Who and how to screen for cancer in at-risk inflammatory bowel disease patients

Research output: Contribution to journalArticle

Abstract

Inflammatory bowel diseases (IBDs) include both Crohn's disease and ulcerative colitis and both diseases are marked by inflammation within the gastrointestinal tract. Due to long-standing inflammation, IBD patients are at increased risk of colorectal cancer, especially patients with chronic inflammation, pancolitis, co-diagnosis of primary sclerosing cholangitis and a longer duration of disease. Small bowel inflammation places Crohn's patients at an increased risk of small bowel cancer. A higher risk of skin cancers, lymphomas and cervical abnormalities is also seen in IBD patients; this is likely related to both disease factors and the presence of immunosuppressive medication. This article reviews which patients are at an increased risk of IBD-associated or IBD treatment-associated cancers, when to begin screening and which screening methods are recommended.

Original languageEnglish (US)
Pages (from-to)731-746
Number of pages16
JournalExpert Review of Gastroenterology and Hepatology
Volume9
Issue number6
DOIs
Publication statusPublished - Jul 1 2015

    Fingerprint

Keywords

  • Biologics
  • colorectal cancer
  • Crohn's disease
  • IBD-associated cancer
  • inflammatory bowel disease
  • lymphoma
  • skin cancer
  • thiopurines
  • Ulcerative colitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this